The patent challenges of the Indian company set to become the world’s biggest biosimilars business
In an exclusive interview Biocon Biologics’ chief IP counsel explains the issues that he and his team focus on – and how an upcoming, big-ticket merger will lead to change
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.